HOSPITAL-ACQUIRED DISEASE TESTING MARKET ANALYSIS

Hospital-acquired Disease Testing Market – Market Insights

Hospital acquired disease or nosocomial infection is a localized or systemic condition in patients which occurs due to adverse reaction caused by infectious toxin agents during medical care, and were absent at the time of admission. Hospital-acquired infections result in prolonged hospital stay, antimicrobial resistance, long-term disabilities, and higher mortality rate. Pathogens responsible for hospital-acquired diseases include viruses, fungal parasites, and bacteria.

Hospital-acquired diseases also include catheter-related blood stream infections, surgical site infections, ventilator-associated pneumonia, and catheter-associated urinary tract infection. The technique used for prevention, diagnosis, and testing of hospital-acquired diseases are microarray, PCR, and solid phase hybridization. Urinary tract infections are most common in patients using urinary catheters as the urethra is located close to the anus, which increases the chances of bacterial invasion from the large intestine into the urinary tract.

The global hospital-acquired disease testing market is expected to be valued at US$ 925.4 million in 2019, and is expected to exhibit a CAGR of 20.0% over the forecast period (2019-2027).

Figure 1. Global Hospital-acquired Disease Testing Market Value (US$ Mn), by Region, 2019

To learn more about this report, request sample copy

Source: Coherent Market Insights Analysis (2020)

Increasing incidence of hospital acquired infections is expected to propel the market growth over the forecast period

Rising incidence of infections such as central line associated bloodstream infection (CLABSI), catheter-related bloodstream infection (CRBSI), and others are expected to drive growth of the hospital-acquired disease testing market over the forecast period. For instance, according to data published during the National Healthcare Safety Network Bloodstream Infection Surveillance in March 2018, around 30,000 CLABSI cases are reported every year in the U.S. CLABSI can prolong the hospital stay, which can increase the cost burden on patients and also lead to mortality.

Furthermore, according to the statistics published by the International Society for Infectious Diseases in March 2018, around 250,000 cases of blood stream infections are reported every year in the U.S. Among these, around 80,000 are catheter-related bloodstream infections (CRBSI) which occur in intensive care units.

Figure 2. Global Hospital-acquired Disease Testing Market Value, (US$ Million), 2016-2027

To learn more about this report, request sample copy

Source: Coherent Market Insights Analysis (2020)

Increasing launches of advanced and efficient testing tools and kits are expected to fuel the growth of the hospital-acquired disease testing market

Manufacturers are focusing on development of advanced testing kits to enhance the efficiency of hospital-acquired disease diagnosis. For instance, in December 2019, F.Hoffmann-La Roche Ltd. received the U.S. Food and Drug Administration (FDA) approval for cobas vivoDx MRSA, a diagnostic test designed to detect the Methicillin-resistant Staphylococcus aureus (MRSA) bacteria. The approval of cobas vivoDx MRSA is intended to aid in the control and prevention of the Methicillin-resistant Staphylococcus aureus (MRSA) infections in healthcare settings.

However, decreasing prevalence of nosocomial infections due to the availability of advanced hospital-acquired disease tests in developed countries is likely to hinder the market growth in near future.

Key Players

Major players operating in the global hospital-acquired disease testing market include Luminex Corporation, Diatherix Laboratories, Life Technologies, Cantel Medical Corporation, Meridian Biosciences Inc, Nordion Inc, Qiagen GmbH, F.Hoffmann-La Roche Ltd., Biomérieux, and Cepheid.